November 05, 2026 4:05pm EST Download as PDF
Related Documents
Company to Host Conference Call on Thursday, November 5, 2026, at 2:30 p.m. PT/5:30 p.m. ET
- Reports record revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million, up 1,782% year-over-year, and record adjusted EBITDA_(1)_ of $77.2 million, up 13% year-over-year for the three months ended September 30, 2026
- Reports net cash provided by operating activities of $117.1 million and free cash flow_(2)_ of $105.4 million for the nine months ended September 30, 2026
ALHAMBRA, Calif., Nov. 5, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the third quarter ended September 30, 2026.

"Our third quarter results demonstrate the growing impact of Astrana's physician-centric, AI-native healthcare operating platform and our team's continued focus on execution," said Brandon Sim, President and Chief Executive Officer of Astrana Health. "We delivered record revenue, record adjusted EBITDA, and double-digit organic earnings growth while continuing to invest in the next phase of our growth. By combining proprietary technology, aligned physician partnerships, and integrated care delivery, we're building a scalable, repeatable model to improve patient outcomes and manage the total cost of care – a value proposition that extends across payer and reimbursement models and positions us to create sustainable long-term value for patients, physician partners, and shareholders."
Financial Highlights for Third Quarter Ended September 30, 2026:
All comparisons are to the three months ended September 30, 2025 unless otherwise stated.
- Total revenue of $1,023.6 million, up 7% from $956.0 million
- Care Partners revenue of $968.8 million, up 8% from $897.7 million
- Net income attributable to Astrana of $13.0 million, up from $0.4 million
- Earnings per share ("EPS") - diluted of $0.26, up from $0.01
- Adjusted EBITDA(1) of $77.2 million, up 13% from $68.5 million
- Adjusted EPS - diluted(3) of $0.71, up 4% from $0.68
Financial Highlights for Nine Months Ended September 30, 2026:
All comparisons are to the nine months ended September 30, 2025 unless otherwise stated.
- Total revenue of $2,961.2 million, up 33% from $2,231.2 million
- Care Partners revenue of $2,811.3 million, up 32% from $2,130.1 million
- Net income attributable to Astrana of $47.1 million, up 186% from $16.5 million
- EPS - diluted of $0.95, up 188% from $0.33
- Adjusted EBITDA(1) of $212.4 million, up 39% from $153.0 million
- Adjusted EPS - diluted(3) of $2.25, up 36% from $1.66
- Net cash provided by operating activities of $117.1 million
- Free cash flow(2) of $105.4 million
| (1) | See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information. |
| (2) | See reconciliation provided with the condensed consolidated statements of cash flows and "Use of Non-GAAP Financial Measures" below for additional information. |
| (3) | See "Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted" and "Use of Non-GAAP Financial Measures" below for additional information. |
Recent Operating Highlights
- Closed the acquisition of an independent practice association in Georgia on October 1, 2026.
- Added two Care Enablement clients, a provider group in Connecticut and a hospital in California, with both expected to onboard onto Astrana's AI-powered technology and managed services platform in early 2027.
- Entered into several new Medicare Advantage payer partnerships effective January 1, 2027, with new health plan partners in markets including Southern California, Texas, and Arizona, supporting continued membership growth across the Astrana platform.
Segment Results for three months ended September 30, 2026:
All comparisons are to the three months ended September 30, 2025 unless otherwise stated.
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||
| (in thousands) | Care Partners | Care Delivery | Care Enablement | Intersegment Elimination | Corporate Costs | Consolidated Total | ||||||||||||||||||
| Total revenues | $ | 968,757 | $ | 91,017 | $ | 92,001 | $ | (128,159) | $ | — | $ | 1,023,616 | ||||||||||||
| % change vs. prior year quarter | 8 | % | 5 | % | 5 | % | ||||||||||||||||||
| Cost of services | 829,490 | 69,116 | 47,915 | (46,453) | — | 900,068 | ||||||||||||||||||
| General and administrative expenses | 77,694 | 22,229 | 18,425 | (81,713) | 31,412 | 68,047 | ||||||||||||||||||
| Depreciation and amortization | 12,480 | 1,263 | 1,226 | — | 653 | 15,622 | ||||||||||||||||||
| Total expenses | 919,664 | 92,608 | 67,566 | (128,166) | 32,065 | 983,737 | ||||||||||||||||||
| Income (loss) from operations | $ | 49,093 | $ | (1,591) | $ | 24,435 | $ | 7 | (1) | $ | (32,065) | $ | 39,879 | |||||||||||
| % change vs. prior year quarter | 94 | % | 56 | % | 4 | % |
| (1) | Income from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table. |
2026 Guidance:
Based on the Company's existing business, current view of existing market conditions, and assumptions, the Company is providing guidance for total revenue and Adjusted EBITDA for the quarter ending December 31, 2026 and narrowing guidance for total revenue, Adjusted EBITDA, and free cash flow for the year ending December 31, 2026.
| Three Months Ending December 31, 2026 | Year Ending December 31, 2026 | |||||||||||||||
| Guidance Range | Guidance Range | |||||||||||||||
| ($ in millions) | Low | High | Low | High | ||||||||||||
| Total revenue | $ | 939 | $ | 1,039 | $ | 3,900 | $ | 4,000 | ||||||||
| Adjusted EBITDA | $ | 48.5 | $ | 61.5 | $ | 261 | $ | 274 | ||||||||
| Free cash flow | $ | 107.5 | $ | 130 |
See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA," "Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow," and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.
Conference Call and Webcast Information:
Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, November 5**,** 2026), during which management will discuss the results of the third quarter ended September 30, 2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:
U.S. & Canada (Toll-Free): +1 (877) 858-9810
International (Toll): +1 (201) 689-8517
The conference call can also be accessed via webcast at:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=PPgZy93u
An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar ) after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov .
Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.
Note About Consolidated Entities
The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Non-controlling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income or loss attributable to non-controlling interests is disclosed in the Company's consolidated statements of income.
About Astrana Health, Inc.
Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.
Today, Astrana supports more than 20,000 providers and approximately 1.5 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the quarter ending and the year ending December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company's ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statement made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.


